Abbott buys CFR Pharma

Abbott Labs (ABT) doubles its Latin American presence with its purchase of Chilean generic drug firm CFR Pharma for $2.9B cash plus assumption of $430M in debt.

The acquisition will add $900M to Abbott's top line in 2015 and double-digit sales growth over the next few years.

CFR markets over 1,000 products. It employs 7,000 people and has R&D and manufacturing facilities in Chile, Colombia, Peru and Argentina.

The Latin American pharmaceutical market is valued at $73B and is forecasted to grow to $124B in four years.

From other sites
Comments (6)
  • vman
    , contributor
    Comments (152) | Send Message
    How-deeeeee partner (bio-med companies) wanting to get into S.America... good open door.
    16 May 2014, 08:05 AM Reply Like
  • Minutemen
    , contributor
    Comments (2287) | Send Message
    Nice aquisition for ABT.
    16 May 2014, 08:06 AM Reply Like
  • 1GreatCFA
    , contributor
    Comments (1362) | Send Message
    This is our most "global" company. Easy to see why. Love the Lab.
    16 May 2014, 09:30 AM Reply Like
  • Andre LaPlume
    , contributor
    Comments (674) | Send Message
    Hate the Drake.
    16 May 2014, 01:23 PM Reply Like
  • Alex2322
    , contributor
    Comments (332) | Send Message
    Love it!!!
    16 May 2014, 10:30 AM Reply Like
  • Willow Street Investments
    , contributor
    Comments (2468) | Send Message
    This is what a good pharma can do rather than PFE's tax games and lack of imagination and disregard for shareholders.
    16 May 2014, 10:48 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs